Kinetics of paclitaxel 2′-N-methylpyridinium mesylate decomposition

AAPS PharmSciTech

Volumn 4, Issue 2, 2003, Pages

  Qasem, Jaber G ^a,b   Bummer, Paul M ^a   Digenis, George A ^a  

^a University of Kentucky   (United States)

^b Perrigo Company   (United States)

Author keywords

Conversion; Micelle; Prodrug; Solubility; Stability

Indexed keywords

PACLITAXEL; PACLITAXEL 2' N METHYLPYRIDINIUM MESYLATE; PACLITAXEL DERIVATIVE; PHOSPHATE; PRODRUG; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MESYLIC ACID DERIVATIVE;

ARTICLE; BLOOD SAMPLING; CATALYSIS; CONTROLLED STUDY; DRUG DECOMPOSITION; DRUG STABILITY; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; MICELLE; PH; QUANTITATIVE ANALYSIS; STRUCTURE ANALYSIS; SURFACE TENSION; TEMPERATURE DEPENDENCE; CHEMISTRY; KINETICS; METABOLISM; SOLUBILITY;

ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; KINETICS; MESYLATES; PACLITAXEL; PRODRUGS; SOLUBILITY;

EID: 23144447156     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt040221     Document Type: Article

References (16)

1. Wani M, Taylor H, Wells M, Coggan P, McPhail A. Plant anti-tumor agent, VI: the isolation and structure of taxol, a novel antileukemic and antitumor agent from taxus brevifolia. J Am Chem Soc. 1971;93:2325-2327.
2. Markman M. Taxol: an important new drug in the management of ovarian cancer. Yale J Biol Med. 1991;64:583-590.
3. McGuire W, Rowinsky E, Rosenheim N. Taxol: a unique anti-neoplastic agent with significant activity in advanced ovarian epithelial neoplasm. Ann Intern Med. 1991;111:273-279.
4. National Cancer Institute. Taxol NSC 125973 [Clinical Brochure]. Bethesda, MD: National Cancer Institute; 1983.
5. Weiss R, Donehower R, Wiernik P, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8:1263-1268.
6. Nicolaou K, Guy R, Pitsinos E, Wrasidlo W. A water soluble prodrug of taxol with self-assembling properties. Angew Chem Int Ed Engl. 1994;34:1583-1587.
7. Deutsch H, Glinski J, Hernandez L. Synthesis of congeners and prodrugs. 3. Water soluble prodrugs of paclitaxel with potent antitumor activity. J Med Chem. 1989;32:788-792.
8. Zhao Z, Kingston D. Modified Taxols. 6. Preparation of water-soluble prodrugs of taxol. J Nat Prod. 1991;54:1607-1611.
9. Vyas D, Wong H, Crosswell A. Synthesis and antitumor evaluation of water soluble taxol phosphates. Bioorg Med Chem Lett. 1993;3:1357-1360.
10. Magri N, Kingston D. Modified taxols. 4. Synthesis and biological activity of taxols modified in the side chain. J Nat Prod. 1988;51:298-306.
11. Feng X, Yuan Y-J, Wu J-C. Synthesis and evaluation of water-soluble paclitaxel prodrugs. Bioorg Med Chem Lett. 2002;12:3301-3303.
12. Zhang X, Jaacson J, Burt H. Development of amphiphilic diblock copolymers as micellar carriers of taxol. Int J Pharm. 1996;132:195-206.
13. Qasem J. The Role of Counter-Ions in the Stability of N-methylpyridinium Prodrugs: A Case Study With N-methylpyridinium Prodrugs of Paclitaxel [dissertation]. Lexington, KY: University of Kentucky; 1999.
14. Engel GL, Farid NA, Faul MM, Richardson LA, Winneroski LL. Salt form selection and characterization of LY333531 mesylate monohydrate. Int J Pharm. 2000;198:239-247.
15. Connors K, Amidon G, Kennon L. Chemical Stability of Pharmaceuticals. New York, NY: John Wiley & Sons; 1979:10-17.
16. Hiemenz P. Principles of Colloid and Surface Chemistry. New York, NY: Marcel Dekker Inc; 1977:100-105.